Literature DB >> 18162237

Indications for hematopoietic cell transplantation in acute leukemia.

Stella M Davies1, Jacob M Rowe, Frederick R Appelbaum.   

Abstract

Based on available data, all adults with AML under age 60 years with matched siblings should be considered for allogeneic transplantation in first remission, except for those with favorable risk cytogenetics and possibly those whose disease has normal cytogenetics and is FLT3/ITD negative and NPM1 positive. Patients with matched siblings not transplanted in first remission should be followed closely so that transplantation in early first relapse can be considered. Those without matched siblings should receive a MUD transplant in first CR if they have higher risk disease. All others should receive standard chemotherapy and consider a matched unrelated transplant or autologous transplant, should they relapse. RIC allogeneic transplantation using either a matched family member or a MUD can be considered for patients age 60 years or greater with AML in second or subsequent remission, or AML in first remission with intermediate or high risk disease.

Entities:  

Mesh:

Year:  2008        PMID: 18162237     DOI: 10.1016/j.bbmt.2007.10.024

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  3 in total

Review 1.  CAR T cells vs allogeneic HSCT for poor-risk ALL.

Authors:  Caroline Diorio; Shannon L Maude
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

2.  Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Authors:  E Brissot; F Rialland; X Cahu; M Strullu; N Corradini; C Thomas; N Blin; X Rialland; E Thebaud; P Chevallier; P Moreau; N Milpied; J L Harousseau; F Mechinaud; M Mohty
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

3.  Early lymphocyte recovery as a predictor of outcome, including relapse, after hematopoietic stem cell transplantation.

Authors:  Juliane Morando; Sérgio Costa Fortier; Ricardo Pasquini; José Zanis Neto; Carmem Maria Sales Bonfim
Journal:  Rev Bras Hematol Hemoter       Date:  2012
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.